{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:10:27Z","timestamp":1790806227758,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001634","name":"University of Galway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","award":["17T-002"],"award-info":[{"award-number":["17T-002"]}],"id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jad.2025.120888","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:44:33Z","timestamp":1765903473000},"page":"120888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Antidepressant efficacy and safety of scopolamine in individuals with bipolar disorder (SCOPE-BD): A randomized double-blind placebo-controlled trial"],"prefix":"10.1016","volume":"397","author":[{"given":"Cerena","family":"Miravalles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru\u00e1n","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison T.","family":"Rossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Quirke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Alberto","family":"Aguilar Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Alvarez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelechi","family":"Chukwudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara M.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hallahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.120888_bb0005","series-title":"Diagnostic and statistical manual of mental disorders: DSM-5. [DSM V]","author":"American Psychiatric, A","year":"2013"},{"issue":"12","key":"10.1016\/j.jad.2025.120888_bb0010","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.clinthera.2010.11.014","article-title":"Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis","volume":"32","author":"Apfel","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2025.120888_bb0015","series-title":"The alcohol use disorders identification test\u202f: guidelines for use in primary health care","author":"Babor","year":"2001"},{"issue":"7","key":"10.1016\/j.jad.2025.120888_bb0020","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archpsyc.63.7.741","article-title":"Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder","volume":"63","author":"Cannon","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.120888_bb0025","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/mp.2010.24","article-title":"Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder","volume":"16","author":"Cannon","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120888_bb0030","author":"Centre, G. H. T"},{"issue":"5","key":"10.1016\/j.jad.2025.120888_bb0035","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14310","article-title":"A randomized controlled trial of intravenous scopolamine versus active-placebo glycopyrrolate in patients with major depressive disorder","volume":"83","author":"Chen","year":"2022","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.120888_bb0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/archpsyc.1978.01770250121012","article-title":"Physostigmine in mania","volume":"35","author":"Davis","year":"1978","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.120888_bb0045","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.biopsych.2009.11.021","article-title":"Replication of scopolamine\u2019s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial","volume":"67","author":"Drevets","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120888_bb0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jad.2014.03.010","article-title":"Antidepressant treatment history as a predictor of response to scopolamine: clinical implications","volume":"162","author":"Ellis","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2025.120888_bb0055","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bdi.12423","article-title":"The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013","volume":"18","author":"Ferrari","year":"2016","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2025.120888_bb0060","series-title":"SCID-5-RV\u202f: Structured Clinical Interview for DSM-5 Disorders - Research Version","author":"First","year":"2015"},{"issue":"1","key":"10.1016\/j.jad.2025.120888_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.2009.1943","article-title":"Antidepressant drug effects and depression severity: a patient-level meta-analysis","volume":"303","author":"Fournier","year":"2010","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jad.2025.120888_bb0070","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archpsyc.63.10.1121","article-title":"Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial","volume":"63","author":"Furey","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2025.120888_bb0075","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/npp.2010.131","article-title":"Scopolamine produces larger antidepressant and antianxiety effects in women than in men","volume":"35","author":"Furey","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2025.120888_bb0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.psychres.2012.01.003","article-title":"Baseline mood-state measures as predictors of antidepressant response to scopolamine","volume":"196","author":"Furey","year":"2012","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.jad.2025.120888_bb0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0006-3223(91)90170-Q","article-title":"The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group","volume":"30","author":"Gillin","year":"1991","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120888_bb0090","series-title":"ECDEU assessment manual for psychopharmacology (Rev. 1976. ed.)","author":"Guy","year":"1976"},{"issue":"3","key":"10.1016\/j.jad.2025.120888_bb0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0033-3182(95)71666-8","article-title":"Global assessment of functioning. A modified scale","volume":"36","author":"Hall","year":"1995","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jad.2025.120888_bb0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2025.120888_bb0105","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","article-title":"The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.jad.2025.120888_bb0110","series-title":"Four Factor Index of Social Status","author":"Hollingshead","year":"1975"},{"key":"10.1016\/j.jad.2025.120888_bb0115","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jad.2025.120888_bb0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11920-011-0239-6","article-title":"Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients","volume":"13","author":"Janowsky","year":"2011","journal-title":"Curr. Psychiatry Rep."},{"issue":"7778","key":"10.1016\/j.jad.2025.120888_bb0125","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(72)93021-8","article-title":"A cholinergic-adrenergic hypothesis of mania and depression","volume":"2","author":"Janowsky","year":"1972","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jad.2025.120888_bb0130","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.12m07706","article-title":"Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study","volume":"73","author":"Khajavi","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.120888_bb0135","article-title":"Bipolar depression: a review of treatment options","volume":"35","author":"Levenberg","year":"2022","journal-title":"Gen Psychiatr"},{"issue":"9","key":"10.1016\/j.jad.2025.120888_bb0140","article-title":"Transdermal scopolamine for treatment-resistant major depressive disorder","volume":"16","author":"Liester","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jad.2025.120888_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jadr.2021.100235","article-title":"The muscarinic-cholinergic system as a target in the treatment of depressive or manic episodes in bipolar disorder: a systematic review and meta-analysis","volume":"6","author":"McCaffrey","year":"2021","journal-title":"Journal of Affective Disorders Reports"},{"key":"10.1016\/j.jad.2025.120888_bb0150","series-title":"Manual for the profile of mood states","author":"McNair","year":"1971"},{"issue":"1","key":"10.1016\/j.jad.2025.120888_bb0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s13063-022-06270-4","article-title":"Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial","volume":"23","author":"Miravalles","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.jad.2025.120888_bb0160","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120888_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-022-01268-7","article-title":"Normalization of impaired emotion inhibition in bipolar disorder mediated by cholinergic neurotransmission in the cingulate cortex","author":"Nabulsi","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.jad.2025.120888_bb0170","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/archpsyc.1988.01800340028004","article-title":"The effects of acute scopolamine in geriatric depression","volume":"45","author":"Newhouse","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.120888_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ijnp\/pyy051","article-title":"Neurophysiological changes associated with antidepressant response to ketamine not observed in a negative trial of scopolamine in major depressive disorder","volume":"22","author":"Park","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2025.120888_bb0180","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/1740774515625186","article-title":"Remarks on designs enriching for placebo non-responders","volume":"13","author":"Rosenkranz","year":"2016","journal-title":"Clin. Trials"},{"issue":"11","key":"10.1016\/j.jad.2025.120888_bb0185","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3357\/AMHP.5456.2019","article-title":"Intranasal scopolamine for motion sickness","volume":"90","author":"Stankovic","year":"2019","journal-title":"Aerosp Med Hum Perform"},{"key":"10.1016\/j.jad.2025.120888_bb0190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jpsychires.2023.01.043","article-title":"The impact of age on antidepressant response: a mega-analysis of individuals with major depressive disorder","volume":"159","author":"Strawn","year":"2023","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jad.2025.120888_bb0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.9758\/cpn.2015.13.1.109","article-title":"Effect of scopolamine butylbromide on clozapine-induced hypersalivation in schizophrenic patients: a case series","volume":"13","author":"Takeuchi","year":"2015","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"2","key":"10.1016\/j.jad.2025.120888_bb0200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/npp.2010.192","article-title":"Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials","volume":"36","author":"Yildiz","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.120888_bb0205","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120888_bb0210","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320938556","article-title":"The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"10","author":"Zhou","year":"2020","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725023304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725023304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:25:59Z","timestamp":1768937159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725023304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"alternative-id":["S0165032725023304"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.120888","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressant efficacy and safety of scopolamine in individuals with bipolar disorder (SCOPE-BD): A randomized double-blind placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.120888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120888"}}